BG Medicine (BGMD +14%) ramps higher after beating Q4 EPS estimates on a narrower-than-expected loss. Revenue jumped nearly 250% Y/Y, driven largely by increased sales of its BGM Galectin-3(R) test, with product margins increasing 10% over the same period from 60% to 70%. Net losses also decreased by 38% Y/Y from $4.7M to $2.9M, primarily from an adjustment of accrued R&D expenses.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs